Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy
- PMID: 12154048
Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy
Abstract
Engagement of CD137 receptor by agonistic monoclonal antibodies (mAb) stimulates IFN-gamma production and eradicates established tumors in syngeneic mouse models. Using IFN-gamma-deficient mice or neutralizing mAb, we demonstrate that IFN-gamma is an absolute requirement for the antitumor effect of CD137 mAb. Despite progressive tumor growth in IFN-gamma-depleted mice, a fully competent CD8(+) cytolytic T cell (CTL) response developed in the lymph nodes. In addition, tumor cell sensitivity to IFN-gamma was not required because expression of a dominant-negative IFN-gamma receptor on the tumor did not affect the therapeutic effect of CD137 mAb. However, in the absence of IFN-gamma, the number of tumor-infiltrating CD8(+) CTLs was drastically decreased. Our results demonstrate that IFN-gamma is a critical factor regulating the infiltration of antigen-specific CTL into the tumor.
Similar articles
-
Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.Cancer Res. 2002 Jun 15;62(12):3459-65. Cancer Res. 2002. PMID: 12067989
-
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.Cancer Res. 2001 Mar 1;61(5):2031-7. Cancer Res. 2001. PMID: 11280763
-
Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db. J Immunother. 2012. PMID: 22735804
-
Immunotherapy with agonistic anti-CD137: two sides of a coin.Cell Mol Immunol. 2004 Feb;1(1):31-6. Cell Mol Immunol. 2004. PMID: 16212918 Review.
-
Therapeutic vaccination with tumor cells that engage CD137.J Mol Med (Berl). 2003 Feb;81(2):71-86. doi: 10.1007/s00109-002-0413-8. Epub 2003 Feb 8. J Mol Med (Berl). 2003. PMID: 12601523 Review.
Cited by
-
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.JCI Insight. 2019 Jun 13;5(14):e125932. doi: 10.1172/jci.insight.125932. JCI Insight. 2019. PMID: 31194697 Free PMC article.
-
Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer.Cancer Sci. 2008 Jan;99(1):31-8. doi: 10.1111/j.1349-7006.2007.00652.x. Epub 2007 Nov 6. Cancer Sci. 2008. PMID: 17986283 Free PMC article.
-
CD8(+) T cells armed with retrovirally transduced IFN-gamma.J Mol Med (Berl). 2007 Jan;85(1):63-73. doi: 10.1007/s00109-006-0107-8. Epub 2006 Nov 16. J Mol Med (Berl). 2007. PMID: 17109130
-
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb.J Immunother Cancer. 2013 May 29;1:3. doi: 10.1186/2051-1426-1-3. eCollection 2013. J Immunother Cancer. 2013. PMID: 24764534 Free PMC article.
-
Integrating costimulatory agonists to optimize immune-based cancer therapies.Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Immunotherapy. 2009. PMID: 20046961 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials